TTRX
Turn Therapeutics Inc.
Price Chart
Latest Quote
$6.03
-0.13 (-2.11%)
Current Price
| Previous Close | $6.16 |
| Open | $6.46 |
| Day High | $6.58 |
| Day Low | $6.01 |
| Volume | 44,712 |
Stock Information
| Shares Outstanding | 29.79M |
| Total Debt | $6.01M |
| Cash Equivalents | $11.22M |
| Net Income | $-3.84M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $179.62M |
| EPS (TTM) | $-0.13 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $178.28M |
| Income | $-3.84M |
| Book/sh | $0.20 |
| Cash/sh | $0.38 |
| Employees | 2 |
Financial Ratios
| Quick Ratio | 2.19 |
| Current Ratio | 2.23 |
| Debt/Eq | 98.17 |
Returns & Margins
| ROE | -129.17% |
Ownership
| Insider Ownership | 63.74% |
| Institutional Ownership | 1.74% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -40.20 |
| P/B | 29.41 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $5.61 |
| SMA50 | $4.46 |
| RSI | 57.91 |
| ATR | 0.7009 |
| Shares Float | 10.83M |
| Short Ratio | 1.56 |
| Rel Volume | 0.69 |
Performance History
| Week | +9.04% |
| Month | +23.06% |
| Quarter | +73.28% |
| 6 Months | +95.78% |
| YTD | +28.57% |
| 10 Years | -13.86% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $6.03 | 45,200 |
| 2026-06-16 | $6.16 | 31,600 |
| 2026-06-15 | $6.42 | 70,400 |
| 2026-06-12 | $6.05 | 55,900 |
| 2026-06-11 | $5.86 | 29,900 |
| 2026-06-10 | $5.53 | 61,100 |
| 2026-06-09 | $5.05 | 43,700 |
| 2026-06-08 | $5.33 | 21,900 |
| 2026-06-05 | $5.28 | 50,600 |
| 2026-06-04 | $5.74 | 48,200 |
| 2026-06-03 | $6.02 | 91,500 |
| 2026-06-02 | $6.42 | 74,600 |
| 2026-06-01 | $6.33 | 268,900 |
| 2026-05-29 | $5.20 | 145,100 |
| 2026-05-28 | $5.31 | 19,900 |
| 2026-05-27 | $5.29 | 13,100 |
| 2026-05-26 | $5.36 | 58,500 |
| 2026-05-22 | $5.13 | 33,200 |
| 2026-05-21 | $4.97 | 112,600 |
| 2026-05-20 | $4.76 | 34,400 |
| 2026-05-19 | $4.55 | 59,400 |
| 2026-05-18 | $4.90 | 133,500 |
About Turn Therapeutics Inc.
Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses. The company was formerly known as Global Health Solutions, Inc and change its name to Turn Therapeutics Inc. in September 2025. Turn Therapeutics Inc. was incorporated in 2015 and is based in Westlake Village, California.
đ° Latest News
Turn Therapeutics Talks GX-03 Phase II Eczema Data Timeline and Non-Systemic Topical Strategy
MarketBeat âĸ 2026-03-02T06:08:41Z
Positive Signs As Multiple Insiders Buy Turn Therapeutics Stock
Simply Wall St. âĸ 2026-02-04T13:17:23Z
Great week for Turn Therapeutics Inc. (NASDAQ:TTRX) insiders who have 59% stake and they havenât stopped buying
Simply Wall St. âĸ 2026-01-08T12:13:33Z
Here Are Mondayâs Top Wall Street Analyst Research Calls: Doximity, KB Home, NVIDIA, Okta, On Holdings, Take-Two Interactive, Vail Resorts, and More
24/7 Wall St. âĸ 2025-12-29T12:52:55Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | |||
| Total Revenue | - | $0 | $0 |
| Operating Revenue | - | $0 | $0 |
| Expenses | |||
| Total Expenses | - | $1,797,124 | $2,308,149 |
| Net Non Operating Interest Income Expense | - | $28,709 | $15,882 |
| Operating Expense | - | $1,797,124 | $2,308,149 |
| General And Administrative Expense | - | $1,551,168 | $2,300,649 |
| Income & Earnings | |||
| Net Income From Continuing Operation Net Minority Interest | - | $-1,768,415 | $-2,292,267 |
| Net Interest Income | - | $28,709 | $15,882 |
| Interest Income | - | $28,709 | $15,882 |
| Normalized Income | - | $-1,768,415 | $-2,292,267 |
| Net Income From Continuing And Discontinued Operation | - | $-1,768,415 | $-2,292,267 |
| Total Operating Income As Reported | - | $-1,797,124 | $-2,308,149 |
| Net Income Common Stockholders | - | $-1,768,415 | $-2,292,267 |
| Net Income | - | $-1,768,415 | $-2,292,267 |
| Net Income Including Noncontrolling Interests | - | $-1,768,415 | $-2,292,267 |
| Net Income Continuous Operations | - | $-1,768,415 | $-2,292,267 |
| Pretax Income | - | $-1,768,415 | $-2,292,267 |
| Interest Income Non Operating | - | $28,709 | $15,882 |
| Operating Income | - | $-1,797,124 | $-2,308,149 |
| Per Share | |||
| Diluted EPS | $-0.12 | $-0.06 | $-0.08 |
| Basic EPS | $-0.12 | $-0.06 | $-0.08 |
| Other | |||
| Diluted Average Shares | $27,716,045 | $29,445,183 | $29,445,183 |
| Basic Average Shares | $27,716,045 | $29,445,183 | $29,445,183 |
| Tax Effect Of Unusual Items | - | $0 | $0 |
| Tax Rate For Calcs | - | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | - | $-1,749,641 | $-2,264,229 |
| Reconciled Depreciation | - | $47,483 | $43,920 |
| EBITDA (Bullshit earnings) | - | $-1,749,641 | $-2,264,229 |
| EBIT | - | $-1,797,124 | $-2,308,149 |
| Diluted NI Availto Com Stockholders | - | $-1,768,415 | $-2,292,267 |
| Research And Development | - | $245,956 | $7,500 |
| Selling General And Administration | - | $1,551,168 | $2,300,649 |
| Other Gand A | - | $1,551,168 | $2,300,649 |
Fetched: 2026-06-16
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 |
|---|---|---|
| Assets | ||
| Net Tangible Assets | $-999,363 | $-684,171 |
| Total Assets | $2,048,889 | $2,013,560 |
| Total Non Current Assets | $950,965 | $811,743 |
| Non Current Prepaid Assets | $8,582 | $8,582 |
| Goodwill And Other Intangible Assets | $821,931 | $769,939 |
| Other Intangible Assets | $821,931 | $769,939 |
| Current Assets | $1,097,924 | $1,201,817 |
| Other Current Assets | $225,325 | $20,820 |
| Cash Cash Equivalents And Short Term Investments | $872,599 | $1,180,997 |
| Cash And Cash Equivalents | $872,599 | $1,180,997 |
| Debt | ||
| Total Debt | $121,036 | $25,156 |
| Long Term Debt And Capital Lease Obligation | $80,376 | $0 |
| Current Debt And Capital Lease Obligation | $40,660 | $25,156 |
| Liabilities | ||
| Total Liabilities Net Minority Interest | $2,226,321 | $1,927,792 |
| Total Non Current Liabilities Net Minority Interest | $1,518,389 | $1,438,013 |
| Non Current Deferred Liabilities | $1,438,013 | $1,438,013 |
| Current Liabilities | $707,932 | $489,779 |
| Payables And Accrued Expenses | $667,272 | $464,623 |
| Equity | ||
| Common Stock Equity | $-177,432 | $85,768 |
| Total Equity Gross Minority Interest | $-177,432 | $85,768 |
| Stockholders Equity | $-177,432 | $85,768 |
| Retained Earnings | $-19,196,013 | $-17,427,598 |
| Other | ||
| Tangible Book Value | $-999,363 | $-684,171 |
| Invested Capital | $-177,432 | $85,768 |
| Working Capital | $389,992 | $712,038 |
| Capital Lease Obligations | $121,036 | $25,156 |
| Total Capitalization | $-177,432 | $85,768 |
| Additional Paid In Capital | $19,017,239 | $17,512,042 |
| Capital Stock | $1,342 | $1,324 |
| Common Stock | $1,342 | $1,324 |
| Non Current Deferred Revenue | $1,438,013 | $1,438,013 |
| Long Term Capital Lease Obligation | $80,376 | $0 |
| Current Capital Lease Obligation | $40,660 | $25,156 |
| Net PPE | $120,452 | $33,222 |
| Gross PPE | $120,452 | $33,222 |
| Other Properties | $120,452 | $33,222 |
Fetched: 2026-06-16
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 |
|---|---|---|
| Free Cash Flow | ||
| Free Cash Flow | $-1,460,780 | $-1,421,986 |
| Operating Activities | ||
| Operating Cash Flow | $-1,361,305 | $-1,377,680 |
| Cash Flow From Continuing Operating Activities | $-1,361,305 | $-1,377,680 |
| Investing Activities | ||
| Capital Expenditure | $-99,475 | $-44,306 |
| Investing Cash Flow | $-99,475 | $-44,306 |
| Cash Flow From Continuing Investing Activities | $-99,475 | $-44,306 |
| Financing Activities | ||
| Issuance Of Capital Stock | $1,152,382 | $500,000 |
| Financing Cash Flow | $1,152,382 | $500,000 |
| Cash Flow From Continuing Financing Activities | $1,152,382 | $500,000 |
| Net Common Stock Issuance | $1,152,382 | $500,000 |
| Common Stock Issuance | $1,152,382 | $500,000 |
| Other | ||
| End Cash Position | $872,599 | $1,180,997 |
| Beginning Cash Position | $1,180,997 | $2,102,983 |
| Changes In Cash | $-308,398 | $-921,986 |
| Net Intangibles Purchase And Sale | $-99,475 | $-44,306 |
| Purchase Of Intangibles | $-99,475 | $-44,306 |
| Change In Working Capital | $-1,856 | $229,741 |
| Change In Payables And Accrued Expense | $202,649 | $208,663 |
| Change In Prepaid Assets | $-204,505 | $1,653 |
| Other Non Cash Items | $8,650 | $662 |
| Stock Based Compensation | $352,833 | $640,264 |
| Depreciation Amortization Depletion | $47,483 | $43,920 |
| Depreciation And Amortization | $47,483 | $43,920 |
| Net Income From Continuing Operations | $-1,768,415 | $-2,292,267 |
| Change In Other Working Capital | - | $19,425 |
Fetched: 2026-06-16